Chemoradiotherapy: Its effectiveness, toxicity, and perspective in the treatment of esophageal cancer

Annals of Thoracic and Cardiovascular Surgery

Volumn 15, Issue 6, 2009, Pages 359-361

  Udagawa, Harushi ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; EDITORIAL; ESOPHAGUS RESECTION; ESOPHAGUS TUMOR; HUMAN; PATIENT SELECTION; PRACTICE GUIDELINE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; HUMANS; NEOADJUVANT THERAPY; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME;

EID: 74249099069     PISSN: 13411098     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (17)

1. Iizuka T, Ide H, Kakegawa T, Sasaki K, Takagi I, et al. Preoperative radioactive therapy for esophageal carcinoma. Randomized evaluation trial in eight institutions. Chest 1988; 93: 1054-8.
2. Okawa T, Kita M, Tanaka M, Ikeda M. Results of radiotherapy for inoperable locally advanced esophageal cancer. Inte J Radiat Oncol Biol Phys 1989; 17: 49-54.
3. Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999; 281: 1623-7.
4. Hironaka S, Ohtsu A, Boku N, Muto M, Nagashima F, et al. Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2-3)N(any) M(0) squamous cell carcinoma of the esophagus. Inte J Radiat Oncol Biol Phys 2003; 57: 425-33.
5. D'Journo XB, Michelet P, Dahan L, Doddoli C, Seitz JF, et al. Indications and outcome of salvage surgery for oesophageal cancer. Eur J Cardiothorac Surg 2008; 33: 1117-23.
6. Tachimori Y, Kanamori N, Uemura N, Hokamura N, Igaki H, et al. Salvage esophagectomy after high-dose chemoradiotherapy for esophageal squamous cell carci- noma. J Thoracic Cardiovasc Surg 2009; 137: 49-54.
7. Moni J, Nori D. The pitfalls and complications of radiation therapy for esophageal carcinoma. Chest Surg Clin N Am 1997; 7: 565-85.
8. Ishikura S, Nihei K, Ohtsu A, Boku N, Hironaka S, et al. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol 2003; 21: 2697-702.
9. Kumekawa Y, Kaneko K, Ito H, Kurahashi T, Konishi K, et al. Late toxicity in complete response cases after definitive chemoradiotherapy for esophageal squamous cell carcinoma. J Gastroenterol 2006; 41: 425-32.
10. Muro K, Ohtsu A, Ishikura S, Boku N, Takiuchi H, et al. A phase II study of chemoradiotherapy in patients with stage II, III esophageal squamous cell carcinoma (ESCC): (JCOG 9906). J Clin Oncol 2007; 25 (18S [June 20 Supplement; abstr 15137]).
11. Igaki H, Kato H, Ando N, Shinoda M, Shimizu H, et al. A randomized trial of postoperative adjuvant chemo- therapy with cisplatin and 5-fluorouracil versus neoadjuvant chemotherapy for clinical stage II/III squamous cell carcinoma of the thoracic esophagus (JCOG 9907). J Clin Oncol 2008; 26 (15S [May 20 Supplement; abstr 4510]).
12. Weichselbaum RR, Posner MR, Ervin TJ, Fabian RL, Miller D. Toxicity of aggressive multimodality therapy including cisplatinum, bleomycin and methotrexate with radiation and/or surgery for advanced head and neck cancer. Int J Radiat Oncol Biol Phys 1982; 8: 909-13.
13. Livingston RB, Stephens RL, Bonnet JD, Grozea PN, Lehane DE. Long-term survival and toxicity in small cell lung cancer. Southwest Oncology Group study. Am J Med 1984; 77: 415-7.
14. Udagawa H, Akiyama H. Surgical treatment of esophageal cancer: Tokyo experience of the three-field technique. Dis Esophagus 2001; 14: 110-4.
15. Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard- dose radiation therapy. J Clin Oncol 2002; 20: 1167-74.
16. Donahue JM, Nichols FC, Li Z, Schomas DA, Allen MS, et al. Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival. Ann Thoracic Surg 2009; 87: 392-9.
17. Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008; 26: 1086-92.